NO314222B1 - Fremgangsmåte for fremstilling av en rekombinant viral partikkel for suppresjon av en neoplastisk fenotype - Google Patents
Fremgangsmåte for fremstilling av en rekombinant viral partikkel for suppresjon av en neoplastisk fenotype Download PDFInfo
- Publication number
- NO314222B1 NO314222B1 NO19911690A NO911690A NO314222B1 NO 314222 B1 NO314222 B1 NO 314222B1 NO 19911690 A NO19911690 A NO 19911690A NO 911690 A NO911690 A NO 911690A NO 314222 B1 NO314222 B1 NO 314222B1
- Authority
- NO
- Norway
- Prior art keywords
- gene
- cells
- retinoblastoma
- cancer
- protein
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 78
- 230000001629 suppression Effects 0.000 title claims description 27
- 230000003612 virological effect Effects 0.000 title claims description 19
- 230000001613 neoplastic effect Effects 0.000 title claims description 11
- 239000002245 particle Substances 0.000 title claims description 10
- 238000002360 preparation method Methods 0.000 title description 4
- 230000008569 process Effects 0.000 title description 2
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 177
- 201000011510 cancer Diseases 0.000 claims abstract description 106
- 201000000582 Retinoblastoma Diseases 0.000 claims description 229
- 108050002653 Retinoblastoma protein Proteins 0.000 claims description 76
- 108700025716 Tumor Suppressor Genes Proteins 0.000 claims description 54
- 102000044209 Tumor Suppressor Genes Human genes 0.000 claims description 54
- 108700025701 Retinoblastoma Genes Proteins 0.000 claims description 47
- 201000008968 osteosarcoma Diseases 0.000 claims description 32
- 239000012634 fragment Substances 0.000 claims description 21
- 238000004519 manufacturing process Methods 0.000 claims description 19
- 239000013598 vector Substances 0.000 claims description 19
- 206010006187 Breast cancer Diseases 0.000 claims description 12
- 208000026310 Breast neoplasm Diseases 0.000 claims description 12
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- 239000013603 viral vector Substances 0.000 claims description 3
- 201000008275 breast carcinoma Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 230000001177 retroviral effect Effects 0.000 claims description 2
- 239000007858 starting material Substances 0.000 claims 6
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 1
- 201000001531 bladder carcinoma Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005296 lung carcinoma Diseases 0.000 claims 1
- 201000001514 prostate carcinoma Diseases 0.000 claims 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 194
- 210000000349 chromosome Anatomy 0.000 abstract description 61
- 230000002759 chromosomal effect Effects 0.000 abstract description 27
- 230000002950 deficient Effects 0.000 abstract description 22
- 206010007269 Carcinogenicity Diseases 0.000 abstract description 16
- 231100000260 carcinogenicity Toxicity 0.000 abstract description 16
- 230000007670 carcinogenicity Effects 0.000 abstract description 16
- 238000010171 animal model Methods 0.000 abstract description 13
- 238000012360 testing method Methods 0.000 abstract description 13
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 abstract description 10
- 238000001415 gene therapy Methods 0.000 abstract description 7
- 238000002560 therapeutic procedure Methods 0.000 abstract description 4
- 239000003256 environmental substance Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 237
- 101150020201 RB gene Proteins 0.000 description 169
- 108010093322 s-formylglutathione hydrolase Proteins 0.000 description 73
- 239000002299 complementary DNA Substances 0.000 description 66
- 102000028528 s-formylglutathione hydrolase Human genes 0.000 description 56
- 230000014509 gene expression Effects 0.000 description 53
- 102000004169 proteins and genes Human genes 0.000 description 53
- 241000700605 Viruses Species 0.000 description 52
- 108020004414 DNA Proteins 0.000 description 48
- 108020004999 messenger RNA Proteins 0.000 description 47
- 235000018102 proteins Nutrition 0.000 description 45
- 239000000047 product Substances 0.000 description 38
- 239000000523 sample Substances 0.000 description 37
- 230000000694 effects Effects 0.000 description 36
- 238000012217 deletion Methods 0.000 description 32
- 230000037430 deletion Effects 0.000 description 32
- 210000001519 tissue Anatomy 0.000 description 32
- 210000004881 tumor cell Anatomy 0.000 description 31
- 230000036952 cancer formation Effects 0.000 description 30
- 230000002068 genetic effect Effects 0.000 description 30
- 208000005623 Carcinogenesis Diseases 0.000 description 29
- 231100000504 carcinogenesis Toxicity 0.000 description 29
- 230000006870 function Effects 0.000 description 28
- 239000003550 marker Substances 0.000 description 28
- 241000699666 Mus <mouse, genus> Species 0.000 description 26
- 230000002779 inactivation Effects 0.000 description 25
- 238000011282 treatment Methods 0.000 description 25
- 150000001413 amino acids Chemical group 0.000 description 24
- 238000010367 cloning Methods 0.000 description 23
- 108700028369 Alleles Proteins 0.000 description 20
- 238000011161 development Methods 0.000 description 17
- 230000018109 developmental process Effects 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 16
- 108010089430 Phosphoproteins Proteins 0.000 description 15
- 102000007982 Phosphoproteins Human genes 0.000 description 15
- 208000015181 infectious disease Diseases 0.000 description 15
- 239000002773 nucleotide Substances 0.000 description 15
- 125000003729 nucleotide group Chemical group 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 14
- 230000035772 mutation Effects 0.000 description 14
- 101150017041 ESD gene Proteins 0.000 description 13
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 13
- 230000007613 environmental effect Effects 0.000 description 13
- 101001010890 Homo sapiens S-formylglutathione hydrolase Proteins 0.000 description 12
- 230000001413 cellular effect Effects 0.000 description 12
- 230000001605 fetal effect Effects 0.000 description 12
- 230000012010 growth Effects 0.000 description 12
- 102000043541 human ESD Human genes 0.000 description 12
- 230000004568 DNA-binding Effects 0.000 description 11
- 206010029260 Neuroblastoma Diseases 0.000 description 11
- 238000002405 diagnostic procedure Methods 0.000 description 11
- 230000009385 viral infection Effects 0.000 description 11
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 10
- 208000008383 Wilms tumor Diseases 0.000 description 10
- 238000001514 detection method Methods 0.000 description 10
- 238000002955 isolation Methods 0.000 description 10
- 238000012216 screening Methods 0.000 description 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 9
- 208000016096 Hereditary retinoblastoma Diseases 0.000 description 9
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- 208000018839 Wilson disease Diseases 0.000 description 9
- 201000008949 familial retinoblastoma Diseases 0.000 description 9
- 210000002950 fibroblast Anatomy 0.000 description 9
- 238000009396 hybridization Methods 0.000 description 9
- 238000011580 nude mouse model Methods 0.000 description 9
- 230000002246 oncogenic effect Effects 0.000 description 9
- 230000000069 prophylactic effect Effects 0.000 description 9
- 108090000371 Esterases Proteins 0.000 description 8
- 108700024394 Exon Proteins 0.000 description 8
- 241000699660 Mus musculus Species 0.000 description 8
- 108700020796 Oncogene Proteins 0.000 description 8
- 102000043276 Oncogene Human genes 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 229940024606 amino acid Drugs 0.000 description 8
- 238000001114 immunoprecipitation Methods 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 238000002741 site-directed mutagenesis Methods 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 7
- 229930193140 Neomycin Natural products 0.000 description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 7
- 108700025695 Suppressor Genes Proteins 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000002744 homologous recombination Methods 0.000 description 7
- 230000006801 homologous recombination Effects 0.000 description 7
- 230000004807 localization Effects 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 229930182817 methionine Natural products 0.000 description 7
- 229960004927 neomycin Drugs 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 230000002207 retinal effect Effects 0.000 description 7
- 238000012163 sequencing technique Methods 0.000 description 7
- 230000005748 tumor development Effects 0.000 description 7
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 201000008808 Fibrosarcoma Diseases 0.000 description 6
- 238000000636 Northern blotting Methods 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000003211 malignant effect Effects 0.000 description 6
- 238000010172 mouse model Methods 0.000 description 6
- 210000004940 nucleus Anatomy 0.000 description 6
- 238000011321 prophylaxis Methods 0.000 description 6
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 6
- 210000001525 retina Anatomy 0.000 description 6
- 108020004705 Codon Proteins 0.000 description 5
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 5
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 5
- 108060001084 Luciferase Proteins 0.000 description 5
- 208000000172 Medulloblastoma Diseases 0.000 description 5
- 241000276498 Pollachius virens Species 0.000 description 5
- 101150003725 TK gene Proteins 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 210000003855 cell nucleus Anatomy 0.000 description 5
- 230000007547 defect Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 210000005260 human cell Anatomy 0.000 description 5
- 230000002458 infectious effect Effects 0.000 description 5
- 238000013507 mapping Methods 0.000 description 5
- 125000001360 methionine group Chemical class N[C@@H](CCSC)C(=O)* 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000009711 regulatory function Effects 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 239000003298 DNA probe Substances 0.000 description 4
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 4
- 108700026244 Open Reading Frames Proteins 0.000 description 4
- 238000012300 Sequence Analysis Methods 0.000 description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 210000005170 neoplastic cell Anatomy 0.000 description 4
- 201000008026 nephroblastoma Diseases 0.000 description 4
- 102000044158 nucleic acid binding protein Human genes 0.000 description 4
- 108700020942 nucleic acid binding protein Proteins 0.000 description 4
- 231100000590 oncogenic Toxicity 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 208000011571 secondary malignant neoplasm Diseases 0.000 description 4
- 208000000587 small cell lung carcinoma Diseases 0.000 description 4
- 210000001082 somatic cell Anatomy 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 241001430294 unidentified retrovirus Species 0.000 description 4
- 241000283707 Capra Species 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- 108010075016 Ceruloplasmin Proteins 0.000 description 3
- 102100023321 Ceruloplasmin Human genes 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 206010064571 Gene mutation Diseases 0.000 description 3
- 101000742859 Homo sapiens Retinoblastoma-associated protein Proteins 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- 108700020978 Proto-Oncogene Proteins 0.000 description 3
- 102000052575 Proto-Oncogene Human genes 0.000 description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 description 3
- 208000016624 Retinal neoplasm Diseases 0.000 description 3
- 108091081024 Start codon Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 108010005774 beta-Galactosidase Proteins 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000000711 cancerogenic effect Effects 0.000 description 3
- 231100000357 carcinogen Toxicity 0.000 description 3
- 239000003183 carcinogenic agent Substances 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000005757 colony formation Effects 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 208000005017 glioblastoma Diseases 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 208000022013 kidney Wilms tumor Diseases 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 230000007257 malfunction Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000011275 oncology therapy Methods 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 210000002826 placenta Anatomy 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000779 smoke Substances 0.000 description 3
- 230000004960 subcellular localization Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 206010042863 synovial sarcoma Diseases 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 230000001131 transforming effect Effects 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 230000005740 tumor formation Effects 0.000 description 3
- 230000000381 tumorigenic effect Effects 0.000 description 3
- 206010069754 Acquired gene mutation Diseases 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 101710132601 Capsid protein Proteins 0.000 description 2
- 101710094648 Coat protein Proteins 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 208000009625 Lesch-Nyhan syndrome Diseases 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 101710125418 Major capsid protein Proteins 0.000 description 2
- 241000713869 Moloney murine leukemia virus Species 0.000 description 2
- 101000742870 Mus musculus Retinoblastoma-associated protein Proteins 0.000 description 2
- 101710141454 Nucleoprotein Proteins 0.000 description 2
- 241000286209 Phasianidae Species 0.000 description 2
- 101710083689 Probable capsid protein Proteins 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 101000895926 Streptomyces plicatus Endo-beta-N-acetylglucosaminidase H Proteins 0.000 description 2
- 208000035317 Total hypoxanthine-guanine phosphoribosyl transferase deficiency Diseases 0.000 description 2
- 208000014070 Vestibular schwannoma Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 208000004064 acoustic neuroma Diseases 0.000 description 2
- 208000037919 acquired disease Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 210000002459 blastocyst Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 230000005907 cancer growth Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 239000013611 chromosomal DNA Substances 0.000 description 2
- 235000019504 cigarettes Nutrition 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 210000000448 cultured tumor cell Anatomy 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000009795 derivation Methods 0.000 description 2
- 238000012631 diagnostic technique Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 229960002963 ganciclovir Drugs 0.000 description 2
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000004077 genetic alteration Effects 0.000 description 2
- 231100000118 genetic alteration Toxicity 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 208000006359 hepatoblastoma Diseases 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 238000002169 hydrotherapy Methods 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000004264 monolayer culture Methods 0.000 description 2
- 230000000869 mutational effect Effects 0.000 description 2
- 230000009826 neoplastic cell growth Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 201000008814 placenta cancer Diseases 0.000 description 2
- 208000024361 placenta neoplasm Diseases 0.000 description 2
- 230000003169 placental effect Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000001566 pro-viral effect Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 230000037439 somatic mutation Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 238000004114 suspension culture Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 231100000588 tumorigenic Toxicity 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- KJDSORYAHBAGPP-UHFFFAOYSA-N 4-(3,4-diaminophenyl)benzene-1,2-diamine;hydron;tetrachloride Chemical compound Cl.Cl.Cl.Cl.C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 KJDSORYAHBAGPP-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 201000000046 Beckwith-Wiedemann syndrome Diseases 0.000 description 1
- 206010061764 Chromosomal deletion Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 241001524679 Escherichia virus M13 Species 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102100034349 Integrase Human genes 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 101710128836 Large T antigen Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 208000035752 Live birth Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 108010084498 Myosin Heavy Chains Proteins 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 241001045988 Neogene Species 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 208000016107 Non-hereditary retinoblastoma Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 1
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
- 108010087776 Proto-Oncogene Proteins c-myb Proteins 0.000 description 1
- 102000009096 Proto-Oncogene Proteins c-myb Human genes 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 102000052708 Recessive Genes Human genes 0.000 description 1
- 108700005079 Recessive Genes Proteins 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000003837 Second Primary Neoplasms Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108010049024 Viral Oncogene Proteins Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000010352 biotechnological method Methods 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 206010005084 bladder transitional cell carcinoma Diseases 0.000 description 1
- 201000001528 bladder urothelial carcinoma Diseases 0.000 description 1
- 210000001109 blastomere Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 208000011654 childhood malignant neoplasm Diseases 0.000 description 1
- 238000003200 chromosome mapping Methods 0.000 description 1
- -1 cigarette smoke Chemical class 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000002559 cytogenic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 201000009409 embryonal rhabdomyosarcoma Diseases 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 230000004545 gene duplication Effects 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 230000008303 genetic mechanism Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 101150117702 lpl3 gene Proteins 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 108091008800 n-Myc Proteins 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 208000029522 neoplastic syndrome Diseases 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 230000005853 oncogenic activation Effects 0.000 description 1
- 230000008266 oncogenic mechanism Effects 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000005059 placental tissue Anatomy 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 208000011581 secondary neoplasm Diseases 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000021092 sugar substitutes Nutrition 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 231100000606 suspected carcinogen Toxicity 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229960001814 trypan blue Drugs 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 201000008903 unilateral retinoblastoma Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4736—Retinoblastoma protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- Plant Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- General Chemical & Material Sciences (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26582988A | 1988-10-31 | 1988-10-31 | |
| PCT/US1989/004808 WO1990005180A1 (en) | 1988-10-31 | 1989-10-30 | Products and methods for controlling the suppression of the neoplastic phenotype |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO911690D0 NO911690D0 (no) | 1991-04-29 |
| NO911690L NO911690L (no) | 1991-06-25 |
| NO314222B1 true NO314222B1 (no) | 2003-02-17 |
Family
ID=23012037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19911690A NO314222B1 (no) | 1988-10-31 | 1991-04-29 | Fremgangsmåte for fremstilling av en rekombinant viral partikkel for suppresjon av en neoplastisk fenotype |
Country Status (9)
| Country | Link |
|---|---|
| EP (2) | EP0440744B1 (fi) |
| JP (1) | JPH03505675A (fi) |
| AT (1) | ATE161039T1 (fi) |
| AU (3) | AU638954B2 (fi) |
| CA (1) | CA2001815C (fi) |
| DE (1) | DE68928491T2 (fi) |
| FI (1) | FI113377B (fi) |
| NO (1) | NO314222B1 (fi) |
| WO (1) | WO1990005180A1 (fi) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7384735B1 (en) | 1986-08-11 | 2008-06-10 | Massachusetts Eye And Ear Infirmary | Retinoblastoma nucleic acids |
| US7223842B1 (en) | 1986-08-11 | 2007-05-29 | Massachusetts Eye And Ear Infirmary | Detection of proteins whose absence is associated with a neoplasm |
| US5851991A (en) * | 1987-08-31 | 1998-12-22 | The Regents Of The University Of California | Therapeutic use of the retinoblastoma susceptibility gene product |
| US7105156B1 (en) | 1987-09-17 | 2006-09-12 | The Regents Of The University Of California | Method of using an adenoviral vector encoding a retinoblastoma protein to treat hyperproliferating cells |
| KR970005049B1 (ko) * | 1990-07-16 | 1997-04-11 | 더 리젠츠 오브 더 유니벌시티 오브 캘리포니아 | 바쿨로비루스 발현 시스템, 이 벡터 시스템을 포함하는 이종성 무척추동물 숙주세포, 상기 시스템에 의해 생산되는 가용성의 정제된 야생형 망막아세포종 폴리펩티드 및 이 폴리펩티드의 생산 방법 |
| US5569824A (en) * | 1991-01-04 | 1996-10-29 | Baylor College Of Medicine | Transgenic mice containing a disrupted p53 gene |
| DE69231734T2 (de) * | 1991-01-16 | 2001-09-20 | Japan Found Cancer | Geerbte und somatische mutationen des apc-gens bei menschlichem colorectal-krebs |
| US6410010B1 (en) | 1992-10-13 | 2002-06-25 | Board Of Regents, The University Of Texas System | Recombinant P53 adenovirus compositions |
| EP0575518A1 (en) | 1991-03-06 | 1993-12-29 | Board Of Regents, The University Of Texas System | Methods and compositions for the selective inhibition of gene expression |
| US5747469A (en) | 1991-03-06 | 1998-05-05 | Board Of Regents, The University Of Texas System | Methods and compositions comprising DNA damaging agents and p53 |
| US5330892A (en) * | 1991-03-13 | 1994-07-19 | The Johns Hopkins University | MCC gene (mutated in colorectal cancer) used for diagnosis of cancer in humans |
| JP3151054B2 (ja) * | 1992-06-25 | 2001-04-03 | 協和醗酵工業株式会社 | 抗ｄｃｃ遺伝子産物モノクローナル抗体 |
| US5496731A (en) * | 1993-03-25 | 1996-03-05 | Xu; Hong-Ji | Broad-spectrum tumor suppressor genes, gene products and methods for tumor suppressor gene therapy |
| US5756668A (en) * | 1994-11-15 | 1998-05-26 | The Johns Hopkins University School Of Medicine | Hypermethylated in cancer polypeptide, HIC-1 |
| US5998205A (en) | 1994-11-28 | 1999-12-07 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
| US6638762B1 (en) | 1994-11-28 | 2003-10-28 | Genetic Therapy, Inc. | Tissue-vectors specific replication and gene expression |
| CA2206205A1 (en) * | 1994-11-28 | 1996-06-06 | Genetic Therapy, Inc. | Tissue-specific treatment, diagnostic methods, and compositions using replication-deficient vectors |
| US6054467A (en) * | 1996-07-05 | 2000-04-25 | Sidney Kimmel Cancer Center | Down-regulation of DNA repair to enhance sensitivity to P53-mediated apoptosis |
| US5958892A (en) | 1996-07-30 | 1999-09-28 | Board Of Regents, The University Of Texas System | 2-methoxyestradiol-induced apoptosis in cancer cells |
| DE59813048D1 (de) * | 1997-10-25 | 2005-10-13 | Roche Diagnostics Gmbh | Suspensions-verpackungszellinien für retrovirusvektoren |
| FR2843526A1 (fr) * | 2002-08-16 | 2004-02-20 | Inst Nat Sante Rech Med | Utilisation d'animaux heterozygotes cdx2+/-pour tester des factures cancerogenes ou anti-cancereux |
| US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| US11311574B2 (en) | 2003-08-08 | 2022-04-26 | Sangamo Therapeutics, Inc. | Methods and compositions for targeted cleavage and recombination |
| US8409861B2 (en) | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4736866B1 (en) * | 1984-06-22 | 1988-04-12 | Transgenic non-human mammals | |
| US4942123A (en) * | 1987-09-17 | 1990-07-17 | The Regents Of The University Of California | ppRB110 -phosphoprotein the retinoblastoma susceptibility gene product |
-
1989
- 1989-10-30 AU AU46350/89A patent/AU638954B2/en not_active Ceased
- 1989-10-30 EP EP89912909A patent/EP0440744B1/en not_active Revoked
- 1989-10-30 AT AT89912909T patent/ATE161039T1/de not_active IP Right Cessation
- 1989-10-30 WO PCT/US1989/004808 patent/WO1990005180A1/en not_active Application Discontinuation
- 1989-10-30 EP EP97105585A patent/EP0792931A3/en not_active Withdrawn
- 1989-10-30 CA CA002001815A patent/CA2001815C/en not_active Expired - Lifetime
- 1989-10-30 JP JP2500324A patent/JPH03505675A/ja active Pending
- 1989-10-30 DE DE68928491T patent/DE68928491T2/de not_active Revoked
-
1991
- 1991-04-25 FI FI911997A patent/FI113377B/fi active
- 1991-04-29 NO NO19911690A patent/NO314222B1/no unknown
-
1993
- 1993-10-15 AU AU49155/93A patent/AU670624B2/en not_active Ceased
-
1996
- 1996-10-25 AU AU70421/96A patent/AU7042196A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP0792931A3 (en) | 1999-05-19 |
| FI911997A0 (fi) | 1991-04-25 |
| WO1990005180A1 (en) | 1990-05-17 |
| JPH03505675A (ja) | 1991-12-12 |
| CA2001815C (en) | 2002-09-03 |
| AU670624B2 (en) | 1996-07-25 |
| AU4635089A (en) | 1990-05-28 |
| ATE161039T1 (de) | 1997-12-15 |
| EP0440744B1 (en) | 1997-12-10 |
| DE68928491T2 (de) | 1998-06-04 |
| FI113377B (fi) | 2004-04-15 |
| AU7042196A (en) | 1997-02-20 |
| EP0792931A2 (en) | 1997-09-03 |
| EP0440744A4 (en) | 1992-07-01 |
| CA2001815A1 (en) | 1990-04-30 |
| AU638954B2 (en) | 1993-07-15 |
| NO911690D0 (no) | 1991-04-29 |
| AU4915593A (en) | 1994-01-13 |
| DE68928491D1 (de) | 1998-01-22 |
| NO911690L (no) | 1991-06-25 |
| EP0440744A1 (en) | 1991-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO314222B1 (no) | Fremgangsmåte for fremstilling av en rekombinant viral partikkel for suppresjon av en neoplastisk fenotype | |
| DK2081586T3 (en) | RSPONDINES AS MODULATORS OF ANGIOGENESE AND VASCULOGENESES | |
| JPH11500614A (ja) | 多重腫瘍異常生長遺伝子 | |
| EP2298878A2 (en) | Compositions and methods for the diagnosis of cancer | |
| Sánchez‐Sánchez et al. | Attenuation of disease phenotype through alternative translation initiation in low‐penetrance retinoblastoma | |
| US20050208652A1 (en) | Isogenic beta-catenin cell lines, and methods of making and using same | |
| CA2522984A1 (en) | Methods and compositions targeting tyrosine kinases for the diagnosis and treatment of osteoarthritis | |
| Islam et al. | Molecular cloning, characterization, and chromosomal localization of a human lymphoid tyrosine kinase related to murine Blk. | |
| WO2020143424A1 (zh) | 胃肠道间质瘤的靶点depdc5及其在诊断和治疗中的应用 | |
| US5858771A (en) | Products and methods for controlling the suppression of the neoplastic phenotype | |
| US7060688B2 (en) | Products and methods for controlling the suppression of the neoplastic phenotype | |
| US7507801B2 (en) | Adapter gene | |
| NZ507787A (en) | Novel mutations in the FREAC3 gene for diagnosis and prognosis of glaucoma and anterior segment dysgenesis | |
| JP5093578B2 (ja) | 受容体型プロテインチロシンホスファターゼＰｔｐｒｚによるＥｒｂＢ４シグナルの抑制 | |
| US9079938B2 (en) | ASPP2 splicing variant | |
| US20140234321A1 (en) | Hunk, a snf1-related kinase essential for mammary tumor metastasis | |
| EP1163335A1 (en) | MATERIALS AND METHODS RELATING TO MODULATION OF p66 EXPRESSION | |
| Mantere | DNA damage response gene mutations and inherited susceptibility to breast cancer | |
| JP2002530349A (ja) | Ｎｆ−ａｔ媒介の心臓肥大、それに関係する方法及び試薬 | |
| Sampson | David J Kwiatkowski, Mary Pat Reeve, Jeremy P Cheadle and Julian R Sampson | |
| Sitwala | Transcriptional and post-translational mechanisms controlling the pattern of DEK expression | |
| EP1785728A1 (en) | Methods and devices for selecting compounds that interact with importin alpha7 and related uses thereof | |
| CA2429856A1 (en) | Adapter protein and gene encoding it | |
| Chidambaram | Wilms' tumor-1 (WT1) protein expression in glioma cells actuates cellular invasiveness—Identifying its target genes | |
| AU2008201172A1 (en) | Methods and Compositions for the Diagnosis of Cancer Susceptibilites and Defective DNA Repair Mechanisms and Treatment Thereof |